Dr. Yoshikatsu Koga graduated and received his medical degree from Kumamoto University in 1999. From 1999 to 2003, he trained at the Department of Gastroenterological Surgery, Kumamoto University. From 2003, he performed basic research into invasive pancreatic cancer during his postgraduate study at Kumamoto University Graduate School of Medicine; he obtained his PhD in 2009. In 2006, he joined the faculty of the Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center (NCC), Japan, as a Research Resident. At the NCC, he investigated a new method of colorectal cancer screening by gene and miRNA expression assay using colonocytes isolated from feces. He also investigated preclinical studies using anti-cancer drugs based on drug delivery systems (DDS). Since 2011, he has been working as a Head at the Section of Experimental Animals, EPOC, NCC. Since 2019, he has been working as a Chief at the Department of Strategic Programs, EPOC, NCC, and has been investigating preclinical studies of armed antibody, organoid/PDX models, and co-clinical trials.
Dr. Yoshikatsu Koga graduated and received his medical degree from Kumamoto University in 1999. From 1999 to 2003, he trained at the Department of Gastroenterological Surgery, Kumamoto University. From 2003, he performed basic research into invasive pancreatic cancer during his postgraduate study at Kumamoto University Graduate School of Medicine; he obtained his PhD in 2009. In 2006, he joined the faculty of the Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center (NCC), Japan, as a Research Resident. At the NCC, he investigated a new method of colorectal cancer screening by gene and miRNA expression assay using colonocytes isolated from feces. He also investigated preclinical studies using anti-cancer drugs based on drug delivery systems (DDS). Since 2011, he has been working as a Head at the Section of Experimental Animals, EPOC, NCC. Since 2019, he has been working as a Chief at the Department of Strategic Programs, EPOC, NCC, and has been investigating preclinical studies of armed antibody, organoid/PDX models, and co-clinical trials.